Skip to main content
Erschienen in: International Journal of Hematology 4/2012

01.10.2012 | Original Article

Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis

verfasst von: Yuhei Kamada, Mamiko Sakata-Yanagimoto, Masashi Sanada, Aiko Sato-Otsubo, Terukazu Enami, Kazumi Suzukawa, Naoki Kurita, Hidekazu Nishikii, Yasuhisa Yokoyama, Yasushi Okoshi, Yuichi Hasegawa, Seishi Ogawa, Shigeru Chiba

Erschienen in: International Journal of Hematology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Single-nucleotide polymorphism genotyping microarray (SNP array) analysis provides detailed information on chromosomal copy number aberrations. To obtain detailed information on genomic abnormalities related to pathogenesis or prognosis of multiple myeloma (MM), we performed 250K SNP array analysis in 39 MM patients and 11 cell lines. We identified an accumulation of deletions and uniparental disomies at 22q12.1. Among the hyperdiploid MM cases, chromosomal imbalance at this locus was associated with poor prognosis. On sequencing, we also found a mutation in the seizure-related 6 homolog (mouse)-like (SEZ6L) gene located at ch.22q12.1 in an MM cell line, NOP1. We further found isolated deletions in 17 genes, five of which are known tumor suppressor genes. Of these, deletion of protein tyrosine phosphatase, receptor type D (PTPRD) was found in three samples, including two patients. Consistent with previous reports, non-hyperdiploid MM, deletion of 13q (del13q) and gain of 1q in non-hyperdiploid MMs were predictive of poor prognosis (p = 0.039, p = 0.049, and p = 0.013, respectively). However, our analysis revealed that unless accompanied by gain of 1q, the prognosis of non-hyperdiploid MM was as good as that of hyperdiploid MM. Thus, SNP array analysis provides significant information useful to understanding the pathogenesis and prognosis of MM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Magrangeas F, et al. Genetic heterogeneity in multiple myeloma. Leukemia. 2005;19(2):191–4.PubMedCrossRef Magrangeas F, et al. Genetic heterogeneity in multiple myeloma. Leukemia. 2005;19(2):191–4.PubMedCrossRef
2.
Zurück zum Zitat Chng WJ, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571–96.PubMedCrossRef Chng WJ, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571–96.PubMedCrossRef
3.
Zurück zum Zitat Largo C, et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 2007;92(6):795–802.PubMedCrossRef Largo C, et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 2007;92(6):795–802.PubMedCrossRef
4.
Zurück zum Zitat Flactif M, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9(12):2109–14.PubMed Flactif M, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9(12):2109–14.PubMed
5.
Zurück zum Zitat Chang H, et al. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 1999;13(1):105–9.PubMedCrossRef Chang H, et al. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 1999;13(1):105–9.PubMedCrossRef
6.
Zurück zum Zitat Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8.PubMedCrossRef Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8.PubMedCrossRef
7.
Zurück zum Zitat Walker BA, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–65.PubMedCrossRef Walker BA, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–65.PubMedCrossRef
8.
Zurück zum Zitat Walker BA, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108(5):1733–43.PubMedCrossRef Walker BA, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108(5):1733–43.PubMedCrossRef
9.
Zurück zum Zitat Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.PubMedCrossRef Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.PubMedCrossRef
10.
Zurück zum Zitat Zojer N, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95(6):1925–30.PubMed Zojer N, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95(6):1925–30.PubMed
11.
Zurück zum Zitat Kato M, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712–6.PubMedCrossRef Kato M, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712–6.PubMedCrossRef
12.
Zurück zum Zitat Sanada M, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–8.PubMedCrossRef Sanada M, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–8.PubMedCrossRef
13.
Zurück zum Zitat Agnelli L, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48(7):603–14.PubMedCrossRef Agnelli L, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48(7):603–14.PubMedCrossRef
14.
Zurück zum Zitat Mullighan CG, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64.PubMedCrossRef Mullighan CG, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64.PubMedCrossRef
15.
Zurück zum Zitat Nannya Y, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65(14):6071–9.PubMedCrossRef Nannya Y, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65(14):6071–9.PubMedCrossRef
16.
Zurück zum Zitat Shaffer LG (2009) An International System for Human Cytogenetic Nomenclature 2009. Shaffer LG (2009) An International System for Human Cytogenetic Nomenclature 2009.
17.
Zurück zum Zitat Nishioka M, et al. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene. 2000;19(54):6251–60.PubMedCrossRef Nishioka M, et al. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene. 2000;19(54):6251–60.PubMedCrossRef
18.
Zurück zum Zitat Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med. 2009;15(3):120–8.PubMedCrossRef Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med. 2009;15(3):120–8.PubMedCrossRef
19.
Zurück zum Zitat Gorlov IP, et al. Seizure 6-like (SEZ6L) gene and risk for lung cancer. Cancer Res. 2007;67(17):8406–11.PubMedCrossRef Gorlov IP, et al. Seizure 6-like (SEZ6L) gene and risk for lung cancer. Cancer Res. 2007;67(17):8406–11.PubMedCrossRef
20.
Zurück zum Zitat Kang GH, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008;88(2):161–70.PubMedCrossRef Kang GH, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008;88(2):161–70.PubMedCrossRef
21.
Zurück zum Zitat Bleeker FE, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat. 2009;30(2):E451–9.PubMedCrossRef Bleeker FE, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat. 2009;30(2):E451–9.PubMedCrossRef
22.
Zurück zum Zitat Bakkus MH, et al. Amplification of the c-myc and the pvt-like region in human multiple myeloma. Oncogene. 1990;5(9):1359–64.PubMed Bakkus MH, et al. Amplification of the c-myc and the pvt-like region in human multiple myeloma. Oncogene. 1990;5(9):1359–64.PubMed
23.
Zurück zum Zitat Broustas CG, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16(11):2939–48.PubMedCrossRef Broustas CG, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16(11):2939–48.PubMedCrossRef
24.
Zurück zum Zitat Sahab ZJ, et al. Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J Cancer. 2010;1:14–22.PubMedCrossRef Sahab ZJ, et al. Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J Cancer. 2010;1:14–22.PubMedCrossRef
25.
Zurück zum Zitat Tada M, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010;101(5):1261–9.PubMedCrossRef Tada M, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010;101(5):1261–9.PubMedCrossRef
26.
Zurück zum Zitat Vazquez A, et al. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer. 2011;128(19):2335–43. Vazquez A, et al. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer. 2011;128(19):2335–43.
27.
Zurück zum Zitat Zhao Y, et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci USA. 2010;107(6):2592–7.PubMedCrossRef Zhao Y, et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci USA. 2010;107(6):2592–7.PubMedCrossRef
28.
Zurück zum Zitat Cavalli LR, et al. Frequent Loss of the BLID Gene in Early-Onset Breast Cancer. Cytogenet Genome Res. 2011;135(1):19–24.PubMedCrossRef Cavalli LR, et al. Frequent Loss of the BLID Gene in Early-Onset Breast Cancer. Cytogenet Genome Res. 2011;135(1):19–24.PubMedCrossRef
29.
Zurück zum Zitat Smadja NV, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229–38.PubMedCrossRef Smadja NV, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229–38.PubMedCrossRef
30.
Zurück zum Zitat Fonseca R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.PubMedCrossRef Fonseca R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.PubMedCrossRef
31.
Zurück zum Zitat Seong C, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101(1):189–94.PubMedCrossRef Seong C, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101(1):189–94.PubMedCrossRef
32.
Zurück zum Zitat Dewald GW, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106(10):3553–8.PubMedCrossRef Dewald GW, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106(10):3553–8.PubMedCrossRef
33.
Zurück zum Zitat Fassas AB, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118(4):1041–7.PubMedCrossRef Fassas AB, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118(4):1041–7.PubMedCrossRef
34.
Zurück zum Zitat Leone PE, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033–41.PubMedCrossRef Leone PE, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033–41.PubMedCrossRef
35.
Zurück zum Zitat Fonseca R, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.PubMedCrossRef Fonseca R, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.PubMedCrossRef
36.
Zurück zum Zitat Zhan F, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001.PubMedCrossRef Zhan F, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001.PubMedCrossRef
37.
Zurück zum Zitat Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–26.PubMedCrossRef Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–26.PubMedCrossRef
38.
Zurück zum Zitat Willis TG, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–81.PubMed Willis TG, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–81.PubMed
39.
Zurück zum Zitat Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67(6):2632–42.PubMedCrossRef Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67(6):2632–42.PubMedCrossRef
40.
Zurück zum Zitat Kohno T, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49(4):342–52.PubMed Kohno T, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49(4):342–52.PubMed
41.
Zurück zum Zitat Mokarram P, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.PubMedCrossRef Mokarram P, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.PubMedCrossRef
42.
Zurück zum Zitat Chan TA, Heguy A. The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle. 2009;8(19):3063–4.PubMedCrossRef Chan TA, Heguy A. The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle. 2009;8(19):3063–4.PubMedCrossRef
43.
Zurück zum Zitat Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42(11):1574–80.PubMedCrossRef Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42(11):1574–80.PubMedCrossRef
44.
Zurück zum Zitat French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia. 2002;16(6):1189–96.PubMedCrossRef French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia. 2002;16(6):1189–96.PubMedCrossRef
45.
Zurück zum Zitat Jenner MW, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9):3291–300.PubMedCrossRef Jenner MW, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9):3291–300.PubMedCrossRef
46.
Zurück zum Zitat Takada S, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol. 2005;75(6):505–10.PubMedCrossRef Takada S, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol. 2005;75(6):505–10.PubMedCrossRef
47.
Zurück zum Zitat de Carvalho F, et al. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985–91.PubMedCrossRef de Carvalho F, et al. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985–91.PubMedCrossRef
48.
Zurück zum Zitat Siwarski D, et al. Structure and expression of the c-Myc/Pvt 1 megagene locus. Curr Top Microbiol Immunol. 1997;224:67–72.PubMedCrossRef Siwarski D, et al. Structure and expression of the c-Myc/Pvt 1 megagene locus. Curr Top Microbiol Immunol. 1997;224:67–72.PubMedCrossRef
49.
Zurück zum Zitat Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006;5(9–10):1213–24.CrossRef Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006;5(9–10):1213–24.CrossRef
50.
Zurück zum Zitat Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.PubMedCrossRef Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.PubMedCrossRef
Metadaten
Titel
Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis
verfasst von
Yuhei Kamada
Mamiko Sakata-Yanagimoto
Masashi Sanada
Aiko Sato-Otsubo
Terukazu Enami
Kazumi Suzukawa
Naoki Kurita
Hidekazu Nishikii
Yasuhisa Yokoyama
Yasushi Okoshi
Yuichi Hasegawa
Seishi Ogawa
Shigeru Chiba
Publikationsdatum
01.10.2012
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2012
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1171-1

Weitere Artikel der Ausgabe 4/2012

International Journal of Hematology 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.